Artelo Biosciences Identifies Lipid Pathway Link For ART26.12 In Multi-Omics Cancer Research Presentation At The CRS 2026 Annual Symposium

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced results utilizing multi-omics analyses that identified a potential mechanistic links across disease models with ART26.12, the Company’s lead selective Fatty Acid Binding Protein 5 (FABP5) inhibitor that was presented at the International Cannabinoid Research Society (ICRS) 2026 Annual Symposium being held in Dijon, France. Artelo researchers evaluated datasets generated across multiple disease models, tissues, and experimental systems to identify common biological pathways associated with treatment with ART26.12, Artelo's FABP5 inhibitor currently in Phase 1 testing. Myles Osborn, Lead Medicinal Chemist at Artelo Biosciences, announced the res...